fda compounding semaglutide news november 2025 Drug compounders sue over declaration ending Wegovy shortage Patients Cut Off From Cheaper

Fullness arrives faster than expected, and protein is the highest nutritional priority

The global GLP-1 market is forecasted to exceed $100 billion by 2030, driven by both diabetes and obesity treatment needs and the effectiveness of these medications in regulating blood sugar and appetite suppressant

pancreatic beta cell hormones (insulin and amylin) gastrointestinal peptides (GLP-1 and GIP)

These injections can be a suitable option for individuals looking to manage their weight and improve their overall health

Challenges and limitations of subcutaneous GLP-1 receptor agonist delivery Because of their peptide-like nature, all GLP-1 receptor agonists are readily degraded in the gastrointestinal system